Puma Biotechnology PBYI
NASDAQ PBYI
$9.55 +0.14 (+1.49%)
As of: Sep 4, 2026 · 3:59 PM EDT

Puma Biotechnology (PBYI) Non Operating Interest Expenses (2018 - 2026)

Analysis

Puma Biotechnology (PBYI) Non Operating Interest Expenses (2018 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -1.00 Mn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -
5 Revolution Medicines 44.33 Bn 44.33 Bn - 23.78 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 39.74 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 82.05 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 93.62 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 20.27 Mn
10 Puma Biotechnology 486.99 Mn 393.08 Mn 44.03 Mn 180,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 180,000.00
Mar 31, 2026 731,000.00
Dec 31, 2025 1.12 Mn
Sep 30, 2025 1.49 Mn
Jun 30, 2025 1.84 Mn
Mar 31, 2025 2.18 Mn
Dec 31, 2024 2.62 Mn
Sep 30, 2024 3.10 Mn
Jun 30, 2024 3.37 Mn
Mar 31, 2024 3.36 Mn
Dec 31, 2023 3.35 Mn
Sep 30, 2023 3.34 Mn
Jun 30, 2023 3.33 Mn
Mar 31, 2023 3.31 Mn
Dec 31, 2022 3.28 Mn
Sep 30, 2022 2.95 Mn
Jun 30, 2022 2.70 Mn
Mar 31, 2022 2.66 Mn
Dec 31, 2021 2.72 Mn
Sep 30, 2021 3.12 Mn